Physician profile
Linda Hubsmith
NPI 1033239611
$3,436.67
in general payments reported to CMS, 2019-2025
27 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $748 · 2023: $1,011 · 2024: $691 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $557.04 | 2021-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.59 | 2021-2025 | Caplyta |
| Alkermes, INC. | $305.84 | 2021-2025 | Aristada, Lybalvi |
| Validus Pharmaceuticals LLC | $292.54 | 2023-2025 | Equetro, Equetro, Raldesy |
| Noven Therapeutics, LLC | $255.69 | 2023-2025 | Xelstrym, Secuado |
| Abbvie INC. | $253.53 | 2021-2024 | |
| Lundbeck LLC | $165.48 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $148.32 | 2021-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $127.43 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $123.73 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $89.77 | 2022-2024 | Jornay Pm |
| Pfizer INC. | $88.61 | 2023 | |
| Axsome Therapeutics, INC. | $86.09 | 2023-2025 | Sunosi, Auvelity |
| Neurocrine Biosciences, INC. | $78.61 | 2021-2024 | Ingrezza |
| Almatica Pharma LLC | $73.88 | 2023-2024 | Gralise, Loreev Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $69.01 | 2024-2025 | Azstarys |
| Tempus Ai, INC | $61.23 | 2024 | |
| Eisai INC. | $59.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.45 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $40.15 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $29.21 | 2023 | Spravato |
| Adlon Therapeutics L.P. | $28.45 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.83 | 2021 | |
| Amgen INC. | $20.04 | 2022 | |
| Neos Therapeutics, Lp | $16.84 | 2022 | |
| Tris Pharma INC | $14.69 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Hubsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.